PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.70
-0.07 (-1.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.77
Open5.77
Bid5.55 x 4000
Ask5.98 x 3100
Day's Range5.65 - 5.99
52 Week Range5.01 - 9.42
Volume1,656,099
Avg. Volume1,814,915
Market Cap481.892M
Beta (3Y Monthly)2.80
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga8 days ago

    The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

    Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...

  • GlobeNewswire9 days ago

    Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase 2 clinical study. The multicenter, randomized, controlled trial will evaluate the efficacy and safety of 1095 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who are PSMA-avid, chemotherapy naïve, and progressed on abiraterone.

  • GlobeNewswire11 days ago

    Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been published in The Journal of Nuclear Medicine. The study entitled, “Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma,” reports the complete results of the pivotal study of AZEDRA. This trial was the largest multicenter, prospective trial to evaluate the safety and efficacy of any therapy in patients with pheochromocytoma and paraganglioma and formed the basis of AZEDRA’s approval by the U.S. Food and Drug Administration (FDA) in July 2018.

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zacks12 days ago

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • Benzinga15 days ago

    Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results'

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) shares were rallying Friday morning in response to positive trial data for a prostate cancer imaging agent.  What Happened The company announced  results ...

  • GlobeNewswire15 days ago

    Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

    -PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease-.

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist23 days ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • Simply Wall St.24 days ago

    Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 32.98% Discount

    I am going to run you through how I calculated the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) by estimating the company’s future cash flows and discounting them to their Read More...

  • GlobeNewswire25 days ago

    Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 11:30 a.m. Eastern Daylight Time.

  • Progenics Pharma's Stock Down on Dismal Phase III Study Data
    Zackslast month

    Progenics Pharma's Stock Down on Dismal Phase III Study Data

    Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.

  • GlobeNewswirelast month

    Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. NCCN Guidelines have been updated with AZEDRA, the first and only FDA approved treatment of patients 12 and older with iobenguane scan positive, locally unresectable and metastatic pheochromocytoma or paraganglioma.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Both AbbVie and Progenics had data results this week for Wall Street to absorb. While shares of AbbVie saw gains on its data for Upadacitinib, an investigational oral agent engineered by the company to selectively inhibit JAK1 and is being studied as a once-daily therapy in atopic dermatitis, shares of Progenics were in the red on missing one endpoint in its phase 3 clinical trial testing of its prostate cancer imaging agent, 1404.

  • Associated Presslast month

    Qualcomm and Tailored Brands rise; Kroger stumbles

    Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...

  • Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today
    Motley Foollast month

    Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today

    A phase 3 trial failed, but all isn't lost for the biotech.

  • Benzingalast month

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...

  • CNBClast month

    After-hours buzz: PVTL, PGNX & more

    Check out the companies making headlines after the bell: Pivotal Software PVTL shares tumbled more than 20 percent in after-hours trading despite reporting second-quarter earnings numbers that beat on both the top and bottom line.

  • MarketWatchlast month

    Progenics stock falls on missed study endpoint

    Progenics Pharmaceuticals Inc. shares fell in the extended session Wednesday after the cancer drug company said one of its imaging agents was not sensitive enough to detect prostate cancer in a clinical study. Progenics shares fell 19% after hours, following a 1.6% decline to close the regular session at $7.30. The company said a late-stage clinical trial found its so-called "1404" imaging agent needed to positively detect prostate cancer with a 60% or more sensitivity but did so with a 47% to 51% range. The imaging agent, however, was able to detect the absence of prostate cancer correctly with a specificity of 71% to 75% compared with the study target of 60% or more.

  • GlobeNewswirelast month

    Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced top line data from its Phase 3 study of 1404, the Company’s prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. The Phase 3 trial evaluated the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.

  • Amicus Therapeutics: Recent Developments, Financial Overview
    Market Realistlast month

    Amicus Therapeutics: Recent Developments, Financial Overview

    In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.

  • How Analysts View Amicus Therapeutics in September
    Market Realistlast month

    How Analysts View Amicus Therapeutics in September

    On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.

  • Analysts Are Bullish on Verastem in September
    Market Realistlast month

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • Why Invitae Stock Rose 23% in Week Ended August 24
    Market Realist2 months ago

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...